Bub1 is required for miR-450a-directed iMEFs proliferation inhibition.

<p>(<b>A</b>) iMEF cells were infected with Ad-Bub1 or RFP for 48 h. Cells were harvested and subjected to western blot analysis. (<b>B</b>) Immunoblotting of Bub1 in extracts from iMEF cells that were infected with Ad-Bub1 and transfected with miRNA-450a-3p mimic both or alone for four different treatments: (i) control-mimic; (ii) miRNA-450a-3p-mimic; (iii) miRNA-450a-3p and Ad-RFP; (iv) miRNA-450a-3p-mimic and Ad-Bub1. (<b>C</b>) Cell proliferation analysis of iMEFs that were treated with four different methods, the same as those used in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0047914#pone-0047914-g005" target="_blank">Fig.5B</a>. (<b>D</b>) Cell cycle analysis of iMEFs that were treated as described in B. (<b>E</b>) Cell apoptosis analysis of iMEFs that were treated as described in B. All the results are representative of three independent experiments.